Literature DB >> 12950377

The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity.

T J Steiner1, A I Scher, W F Stewart, K Kolodner, J Liberman, R B Lipton.   

Abstract

This study estimates the 1-year prevalence of migraine in adults in England in relation to the major demographic variables of age, gender and ethnicity, and describes some of its features, including aspects of consequential disability. A telephone survey was conducted of a random sample (n = 4007) of the population aged 16-65 years of mainland England using a previously validated diagnostic interview. The response rate was 76.5%. Overall, 7.6% of males and 18.3% of females reported migraine with or without aura within the last year meeting diagnostic criteria closely approximate to those of the International Headache Society. Prevalence of migraine varied with age, rising through early adult life and declining in the late 40s and early 50s. Prevalence was higher in Caucasians than in other races. Attack rates were > or = 1/month in most migraineurs, and most experienced interference with daily activities in > or = 50% of their attacks. On average, an estimated 5.7 working days were lost per year for every working or student migraineur, although the most disabled 10% accounted for 85% of the total. Results were in keeping with those from surveys in other countries. If these findings in mainland England are projected to the entire UK population, we estimate that 5.85 million people aged 16-65 years experience 190 000 migraine attacks every day and lose 25 million days from work or school each year because of them. Migraine is an important public health problem in the UK, associated with very substantial costs.

Entities:  

Mesh:

Year:  2003        PMID: 12950377     DOI: 10.1046/j.1468-2982.2003.00568.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  105 in total

Review 1.  Evidence of Potential Mechanisms of Acupuncture from Functional MRI Data for Migraine Prophylaxis.

Authors:  Ching-Mao Chang; Chun-Pai Yang; Cheng-Chia Yang; Po-Hsuan Shih; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2021-05-26

2.  Acupuncture for migraine prophylaxis: a randomized controlled trial.

Authors:  Ying Li; Hui Zheng; Claudia M Witt; Stephanie Roll; Shu-guang Yu; Jie Yan; Guo-jie Sun; Ling Zhao; Wen-jing Huang; Xiao-rong Chang; Hong-xing Zhang; De-jun Wang; Lei Lan; Ran Zou; Fan-rong Liang
Journal:  CMAJ       Date:  2012-01-09       Impact factor: 8.262

Review 3.  Controversies in migraine: monotherapy.

Authors:  Domenico D'Amico
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

4.  Statins for all: should patients who have migraine with aura be on a statin?

Authors:  David Kernick
Journal:  Br J Gen Pract       Date:  2015-11       Impact factor: 5.386

5.  Guest Editorial.

Authors:  M S Chong
Journal:  Br J Pain       Date:  2012-08

6.  Migraine prevalence, socioeconomic status, and social causation.

Authors:  Walter F Stewart; Jason Roy; Richard B Lipton
Journal:  Neurology       Date:  2013-08-29       Impact factor: 9.910

7.  Lifetime prevalence and correlates of migraine among women in a pacific northwest pregnancy cohort study.

Authors:  Ihunnaya O Frederick; Chunfang Qiu; Daniel A Enquobahrie; Sheena K Aurora; B Lee Peterlin; Bizu Gelaye; Michelle A Williams
Journal:  Headache       Date:  2013-08-28       Impact factor: 5.887

8.  Easing the pain: challenges and opportunities in headache management.

Authors:  David P B Watson
Journal:  Br J Gen Pract       Date:  2008-02       Impact factor: 5.386

Review 9.  Prevalence of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andree
Journal:  J Headache Pain       Date:  2010-05-16       Impact factor: 7.277

10.  Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations.

Authors:  Monali Bhosle; Joshua S Benner; Mitch Dekoven; Jeff Shelton
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.